The single-dose antibiotic with a one-hour infusion is approved to treat MRSA and other skin infections.
Melinta Therapeutics has launched Kimyrsa (oritavancin), a lipoglycopeptide antibiotic to treat acute bacterial skin and skin structure infections (ABSSSI) in a single, one hour, 1,200 mg infusion.
The FDA had approved Kimyrsa in March 2021, for the treatment of adult patients with ABSSSI caused by susceptible isolates of designated Gram-positive microorganisms, including methicillin-resistant Staphylococcus aureus (MRSA). The most common adverse reactions (≥3%) in patients treated with oritavancin products were headache, nausea, vomiting, limb and subcutaneous abscesses, and diarrhea.
“Kimyrsa is a direct response to the requests of the medical community to provide an oritavancin product with a shorter infusion time, additional diluent options, and lower infusion volume,” John Harlow, chief commercial officer of Melinta said in a statement.
The company already markets Orbactiv, a oritavancin that was approved in 2014 and has a three-hour infusion time.
ABSSSIs affect about 14 million patients in the United States each year and are responsible for more than 3 million visits to the emergency room annually, according to press release issued by Melinta.
An increase in MRSA skin infections has been a major contributor to the U.S. burden of skin infections. In one study, investigators found that the rate of clinically-diagnosed skin and soft tissue infections was 496 per 10,000 person-years, with MRSA infections being 46% of the Staphylococcus aureus infections that were cultured.
Treatment of ABSSSI is not straightforward, and poor outcomes are characterized by spreading infection, bacteremia, septic shock, osteomyelitis, recurrence, prolonged hospitalization, or death.
Ruxolitinib Cream Proves Safe for Young Children with Atopic Dermatitis
July 22nd 2024These results were found in the TRuE-AD3 study that was presented at the Society for Pediatric Dermatology meeting earlier this month, revealing the latest round of data collected in the TRuE-AD1 and TRuE-AD2 series of studies.
Read More
FDA Issues Complete Response for High-Dose Opioid Rescue Med
July 16th 2024OX124 is a nasal spray provides rapid absorption of naloxone for patients experiencing an opioid overdose. The FDA would like to see additional technical data, as well as data on whether patients can correctly use the device.
Read More
Study Reveals Severe Impact of Atopic Dermatitis on Women's Quality of Life and Reproductive Health
July 15th 2024Although AD is a common condition, it’s impact on sexual function and reproductive health is not well understood. In addition, many women with AD are undertreated during pregnancy due to concerns about medication side effects.
Read More